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Abstract
Background: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual 
research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended 
in daily practice.
Methods: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 
35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and 
during a 60-day pharmacovigilance period.
Results: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and 
in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy 
pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight 
patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P = .043). A total of 5.2% 
of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic 
drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at 
least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic 
doses and antipsychotic polytherapy (85.2% vs 45.5%, P < .001).
Conclusions: These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in 
Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of 
determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-
acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.
Keywords: Antipsychotic, first episode psychosis, pharmacovigilance, polytherapy, psychotropic drugs, schizophrenia.
Introduction
A first episode of psychosis (FEP) is a frequent condition suffered 
by approximately 3% of the general population, beginning usually 
in youth (Perala et al., 2007). The characterization of the popula-
tion with a FEP has become an area of main interest for research 
(Bernardo and Bioque, 2014), with a growing number of studies in 
the last decade worldwide (McEvoy et al., 2007; Bertelsen et al., 
2008; Castro-Fornieles et al., 2008; Kahn et al., 2008; Bertani et al., 
2011). The conduct of longitudinal research in early phases of 
the illness has become especially relevant, because it avoids the 
effect of confounding variables such as the influence of antipsy-
chotic treatment, comorbidities, or chronicity (Kahn et al., 2008).
Antipsychotic medications are known to improve the out-
comes and reduce the relapse rates in early phases of schizophre-
nia and related disorders (Alvarez-Jimenez et al., 2009; Barnes and 
Psychopharmacology, 2011). However, there is still some contro-
versy about important aspects of the pharmacological treatment 
of the FEP, including the supposed superior effectiveness of the sec-
ond-generation antipsychotic (SGA) over the first generation (FGA) 
(Crossley et al., 2010; Leucht et al., 2013). Currently, the major part 
of the guidelines on the treatment of schizophrenia focuses on side 
effects rather than differential efficacy and recommend starting 
with low doses in FEP, with careful side effect monitoring (American 
Psychiatric Association, 2004; Deutsche Gesellschaft für Psychiatrie 
Psychotherapie und Nervenheilkunde, 2006; Grupo de trabajo de 
la Guía de Práctica Clínica sobre la Esquizofrenia y el Trastorno 
Psicótico Incipiente. Fòrum de Salut Mental, 2009; National Institute 
of Clinical Excellence, 2009; Barnes and Psychopharmacology, 2011).
As all pharmacological treatments, all antipsychotics can 
cause adverse drug reactions (ADRs) (Leucht et al., 2013), but an 
adequate antipsychotic dosage is related to a decrease in mor-
tality (Torniainen et al., 2014). Some of these side effects may 
cause symptoms similar to those of schizophrenia, such as sec-
ondary negative symptoms (Bernardo et al., 2013), while some 
subjects may develop side effects that are new symptoms, such 
as galactorrhea, disrupted sexual function, or sedation. The sub-
jective distress and the functional impairment that result from 
these ADRs are associated with the poor adherence rates to 
these treatments (Sendt et al., 2015).
Apart from effectiveness and tolerability, other important 
issues to elucidate are the role of long-acting injectable antipsy-
chotics (LAIAs) in FEP patients (Patel et al., 2010; Zhornitsky and 
Stip, 2012; Manchanda et al., 2013; Correll, 2014; Kishimoto et al., 
2014; Subotnik et al., 2015), the real rates of antipsychotic poly-
therapy, and the coadjuvant treatments such as antidepressants 
or benzodiazepines (Gallego et al., 2012).
In this context, the “Phenotype-genotype and environmental 
interaction. Application of a predictive model in first psychotic 
episodes” (PEPs project) was a multicenter, prospective, longitu-
dinal, naturalistic study designed to evaluate clinical, neuropsy-
chological, neuroimaging, biochemical, and genetic variables in 
a sample of 335 FEP patients in Spain matched with 253 healthy 
controls (Bernardo et al., 2013). Due to the naturalistic design of 
the PEPs project, participants maintained their usual treatment. 
This feature has allowed, for the first time to our knowledge, to get 
a global picture of the usual treatment and outcomes in patients 
with a FEP in Spain (Mas et al., 2012), being a unique opportunity 
to study treatment prescription patterns in a real life sample of 
335 FEP subjects, together with the presence of ADRs.
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One of the aims of the PEPs Project was to get as close as pos-
sible to the actual daily practice with FEP, following a naturalistic 
design that represented the whole natural history of psychotic 
disorders (Bernardo et al., 2013). Therefore, one of the strengths 
of this study was that the age of inclusion was wide, including 
patients from 7 to 35 years, with the aim of covering the whole 
range of ages at which a FEP may appear. Previous studies with 
FEP (especially clinical trials) generally exclude the population 
with early onset psychosis, which may be a bias because of the 
worse prognosis of this subset of patients (Arango et al., 2012). 
This wide window of age pointed to the fact that the average age 
of this sample tends to be inferior to other large studies with 
large FEP cohorts such as the OPUS or EUFEST trials (Bertelsen 
et al., 2008; Kahn et al., 2008). Besides, patients with suicide idea-
tion or a drug use disorder, frequently excluded from FEPs stud-
ies, were allowed to participate (Bernardo et al., 2013).
This article aims to describe the prescription patterns in a 
multicenter, naturalistic study with more than 300 FEP with a 
wide age range (7–35 years), putting a particular emphasis on 
practices that are not usually first-line recommendations in 
international guidelines, such as polypharmacy, the use of 
LAIAs, or clozapine, and how these patterns were related to 
security/tolerance issues.
Methods
Subjects
The 16 centers participating in the PEPs project recruited a total 
of 335 patients with a FEP from April 2009 to April 2012. Patients 
were recruited from 16 centers located throughout the Spanish 
territory with experience in performing and assessing diagno-
ses, in the use of semi-structured interviews and clinical scales, 
and in treating this population. Fourteen of these teams were 
members of the Centro de Investigaciones Biomédicas en Red en 
Salud Mental (CIBERSAM), the Spanish network of translational 
research in neuroscience aspects related to health and mental ill-
ness, together with 2 collaborator centers (Bernardo et al., 2013). 
Every patient who met the inclusion criteria and was attended 
at these facilities during the recruitment period was invited to 
participate in the study on either an inpatient or outpatient basis.
The inclusion criteria for patients were: age between 7 and 
35 years, presence of first psychotic symptoms (positive symp-
toms or disorganization) of at least 1 week duration in the last 
12  months, and speak Spanish correctly. The exclusion crite-
ria for patients were: (1) mental retardation according to the 
Diagnostic and Statistical Manual of mental disorders, 4th 
edition (DSM-IV) criteria (American Psychiatric Association 
(Washington), 1994), (2) history of head trauma with loss of con-
sciousness, and (3) presence of an organic disease with mental 
repercussions.
Since this was a naturalistic study, there were no spe-
cific guidelines for treatments (drugs and/or psychotherapy). 
Treatment with antipsychotics did not exceed 12  months at 
study entry. All scales included in the PEPs project protocol, 
except those self-administered, were administered by expert cli-
nicians. The rationale for these criteria and the complete clini-
cal protocol used in the PEPs project were previously published 
elsewhere (Bernardo et al., 2013).
The study was approved by the investigation ethics commit-
tees of all participating clinical centers. Informed consent was 
obtained from all participants. In case of children under 18 years 
of age, patients assented to participate and parents or legal 
guardians gave written informed consent before their inclusion.
Diagnostic, Demographic, and Clinical Data 
Collection
The Spanish translation of the Kiddie-Sads-Present and Lifetime 
Version (K-SADS-PL) (Kaufman et al., 1997) was used to assess 
current and past psychopathology in children and adoles-
cents according to DSM-IV criteria, and the Structured Clinical 
Interview for DSM Disorders (SCID) parts I and II (SCID-I & II), with 
a Spanish translation available, was used for adults (American 
Psychiatric Association, 1994; First et al., 1994, 1999). The psy-
chopathological assessment was performed using the Positive 
and Negative Syndrome Scale (Kay et al., 1987), the Young Mania 
Rating Scale (Young et  al., 1978), and the Montgomery-Asberg 
Depression Rating Scale (Montgomery and Asberg, 1979). The 
Global Assessment of Functioning Scale, and the Children’s 
Global Assessment Scale were used to measure the global sever-
ity of symptoms and level of functioning (Endicott et al., 1976; 
Shaffer et al., 1983). At baseline, a complete personal and fam-
ily history was compiled, including a register of lifetime drug 
history. In every evaluation, the information of which drugs the 
subjects were taking, the dosage, and the presence of ADRs was 
collected.
Calculation of Prescribed Daily Doses
For the first 60 days after the inclusion of the patient in the PEPs 
project, all psychotropic drugs prescribed to every patient were 
recorded, independently of the dose and separating different 
formulations of the same substance. Thus, a number expressing 
the sum of concomitant prescriptions for each treatment day 
was obtained.
The prescribed daily dose (PDD) for a drug was defined as the 
daily dose of a drug formulation, oral or injectable, calculated 
separately for each treatment day of an individual patient who 
was treated with this particular drug formulation for at least 3 
consecutive days (irrespective of the dose). Different formula-
tions of the same drug were separated. The PDD of LAIAs was 
calculated by dividing the given dose by the number of days 
until the next depot injection.
To compare the different antipsychotics between them, the 
PDDs doses of antipsychotics were converted to an estimated 
equivalent amount of chlorpromazine (CPZ) following the inter-
national consensus (Gardner et al., 2010).
Baseline polypharmacy was registered considering simul-
taneous treatment in the same patient with one antipsychotic 
together with an antidepressant, an anticholinergic drug, a 
mood stabilizer, a benzodiazepine, or another antipsychotic 
used at the same time.
ADR Evaluation
To assess in detail the ADRs, 2 procedures were followed: (1) spon-
taneous reports of ADR; (2) systematic assessment of the effects 
targeted (like metabolic syndrome, cardiotoxicity or extrapyram-
idal symptoms) from physical examination (electrocardiogram, 
antipsychotic plasmatic levels, and general blood tests) and 2 
scales administrated in every follow-up visit: (1) the Scale of the 
Udvalg for Kiniske Undersogelser (Lingjaerde et al., 1987), a com-
prehensive rating scale designed to assess general side effects of 
psychotropic drugs; and (2) the Simpson-Angus Scale (Simpson 
and Angus, 1970), included to evaluate the extrapyramidal side 
effects. Drug-induced Parkinsonism is a common and poorly tol-
erated adverse effect, classically related to typical antipsychotics 
and determinate atypical antipsychotics at higher doses.
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Investigators also reported any specific treatment or 
change in the prescription due to ADR appearance, including 
antipsychotic discontinuation, dose reduction, or start of an 
anticholinergic drug.
Those ADRs that made the clinician change the usual prac-
tice by, for example, requesting a blood test that was not previ-
ously scheduled, sending the patient to the emergency room, 
or admitting the patient to the hospital were considered as 
serious.
Data Processing and Statistical Analysis
The tool GRIDSAM was used for data entry, allowing the differ-
ent centers to capture the data by means of a multi-grid com-
puterized system, which not only integrates all the available 
information but also facilitates a more efficient data exploita-
tion and management (Bernardo et al., 2013).
Differences in baseline demographic and clinical character-
istics between patients and controls were assessed using Chi-
square, t test, or nonparametric Mann-Whitney U test, according 
to the distribution and scales of the variables. Binary logis-
tic regression was performed to assess the impact of different 
covariates on the likelihood that any ADRs would be reported. 
A value of P < .05 was taken to be statistically significant. Data 
was managed and analyzed with the IBM SPSS Statistics v.20 
(IBM Corp, 2011).
Results
Baseline Clinical Characteristics and Psychotropic 
Drug Treatment
A total of 335 patients with a FEP were included in the PEPs pro-
ject and completed the baseline visit. Baseline demographic, 
clinical, and psychotropic drug treatment characteristics are 
presented in Table 1.
A total of 280 (83.6%) patients were diagnosed of nonaffec-
tive psychotic disorders, and 55 subjects (16.4%) diagnosed with 
DSM-IV affective disorders (unipolar depression or bipolar dis-
order) with psychotic features or schizoaffective disorder were 
classified as “affective psychosis.”
At baseline, patients had been treated with antipsychotics 
for a mean of 54.08 days. Thirty (9%) patients were not taking 
any antipsychotic at baseline, including those who were antip-
sychotic naïve and those who have discontinued previous treat-
ments. Only 3.7% of the prescriptions included a FGA. Of those 
subjects who were taking antipsychotics at baseline, 73 (24%) 
were receiving an antipsychotic polytherapy pattern (detailed 
antipsychotic mono/polytherapy patterns in supplementary 
Data 1). The rates of antipsychotic polytherapy in the nonaf-
fective vs affective diagnosis groups were almost identical. The 
most frequent patterns of prescription were monotherapy of 
olanzapine (n = 76), risperidone (n = 74), and aripiprazole (n = 32). 
The most frequent antipsychotic polytherapy patterns were ris-
peridone plus olanzapine (n = 15) and aripiprazole plus olanzap-
ine (n = 9). Eight patients with a FEP were taking clozapine, all 
of them in monotherapy and all diagnosed with a nonaffective 
psychotic disorder.
A total of 87.2% of the patients were receiving adequate 
doses of antipsychotic, according to the recommended dose 
range in the specifications of the product for Spain for the 
patient age (AEMPS, 2014) (see online supplementary Data 2). 
Patients with polytherapy received more frequently lower doses 
(8.2% vs 2%, P = .028) or higher (16.4% vs 6.5%, P = .014) of antip-
sychotics than the recommended ones compared with patients 
receiving monotherapy, with a moderate effect size (Cramer’s 
V= 0.2, P = .002).
Sixteen (5.2%) of the FEP patients included in the PEPs project 
were being treated with LAIAs. All these treatments were risp-
eridone LAI, and all except one went with oral supplementation.
Patients diagnosed of affective psychoses received anti-
depressant drugs (21.8% vs 10.4%, P = .02) and mood stabiliz-
ers (45.5% vs 7.5, P < .001) more frequently than nonaffective 
psychoses.
Table  1. Baseline Demographic, Clinical, and Psychotropic Drug 
Treatment Characteristics
Patients
(n = 335)
Age (y) 23.58 ± 6.00
Gender, n (%)
 Male 225 (67.2)
 Female 110 (32.8)
Ethnic group, n (%)
 Caucasian 284 (84.8)
 Gipsy 6 (1.8)
 Maghrebian 8 (2.4)
 Sub-Saharan 4 (1.2)
 Asian 4 (1.2)
 Caribbean 8 (2.4)
 Hispanic 17 (5.1)
 Other 4 (1.2)
Diagnosis, n (%)
 Affective psychosis 55 (16.4)
 Non-affective psychosis 280 (83.6)
Psychopathology scales scores
 PANSS 74.95 ± 24.57
 Young 9.26 ± 10.48
 Montgomery-Asberg 12.94 ± 9.82
 Overall functioning score (GAF/C-GAS) 50.92 ± 19.66
Subjects antipsychotic treatment, n (%)
 No antipsychotics 31 (9.3)
 Antipsychotic monotherapy 232 (69.2)
 Antipsychotic polytherapy 73 (24)
  2 antipsychotics  67 (20)
  3 antipsychotics 5 (1.5)
  4 antipsychotics 1 (0.3)
Antipsychotic dosage, n (%)
 Lower 12 (3.9)
 Adequate 265 (87.2)
 Higher 27 (8.9)
Route of antipsychotic, n (%)
 Only oral 291 (94.8)
 Only long acting injection 1 (0.3)
 Both 15 (4.9)
Subjects with other treatments, n (%)
 Anticholinergics 41 (12.2)
 Antidepressants 41 (12.2)
 Mood stabilizers 46 (13.7)
 Benzodiazepines 130 (38.8)
Affective psychosis includes DSM-IV unipolar depression or bipolar disorder 
with psychotic features and schizoaffective disorder diagnosis.
Recommended dose range according to the patient age and the specifications 
of the product to Spain
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Drug Treatment during the 2-Month 
Pharmacovigilance Period
Patients were followed in a pharmacovigilance period during 
the first 60 days after their inclusion in the PEPs project. Baseline 
treatment was continued during this period. Any changes or dis-
continuations were registered. Seventeen patients (4.78%) were 
not taking any antipsychotic during this period, and 14 patients 
(4.1%) did not complete the follow-up study, so 302 FEP subjects 
completed the 2-month follow-up study with at least one antip-
sychotic prescription.
During this period, a total of 420 antipsychotic prescriptions 
were made, 1.38 per patient being treated. Table 2 presents the 
PDDs of antipsychotic medications during the pharmacovigi-
lance period.
Drugs prescribed at the highest equivalent doses of CPZ 
were paliperidone, amisulpride, and zuclopenthixol, with 
higher doses than those collected in the ATC/DDD index 
of the World Health Organization (WHO, 2014). Quetiapine, 
ziprasidone, and clozapine were prescribed in the lowest 
equivalent doses.
There was a statistically significant decrease in the antip-
sychotic dosage between baseline visit and the 2-month visit 
(t = 5.18, P < .001) but not in the number of subjects reporting any 
ADRs (81 vs 73).
Table 3 presents the cumulative daily dose of antipsychotics, 
separated by different groups. Males received higher doses of antip-
sychotics than women (P = .043). The patients receiving anticholin-
ergic drugs were also those with higher doses of antipsychotic.
ADRs during the Pharmacovigilance Period
A total of 119 patients (35.52%) reported at least one ADR during 
the pharmacovigilance period. A total of 181 ADRs were reported 
(collected in Table 4), none of which was reported as serious.
The appearance of ADRs was related to higher doses of antip-
sychotic prescriptions; the mean daily CPZ dose of the group of 
patients who reported at least one ADR was higher (598.9 vs 
482.22 mg; t test = 2.32, P = .021).
The percentage of patients who reported at least one ADR 
during the pharmacovigilance period was higher in those 
patients treated with antipsychotic polytherapy than in those 
Table 2. Prescribed Daily Dose (PDD) of Antipsychotic Medications during the 2-Month Pharmacovigilance Period
Antipsychotic
Number of  
Patients (%)
PDD Mean  
Dose (mg) PDD Range
Chlorpromazine  
Equivalent Mean Dose
Risperidone 123 (29.3) 3.79 (3.36–4.21) 0.5–12 379.34 (336.74–421.95)
Olanzapine 114 (27.1) 12.51 (11–14.02) 2.5–40 375.55 (330.22–420.87)
Aripiprazole 63 (15) 13.37 (11.27–15.47) 5–30 267.54 (225.5–309.59)
Paliperidone 36 (8.6) 6.66 (5.27–8.05) 3–18 444.48 (352.01–536.94)
Quetiapine 35 (8.3) 311.35 (240.51–382.19) 50–900 249.08 (192.41–305.75)
Amisulpride 16 (3.8) 580.20 (330.05–830.35) 50–1600 498.97 (283.84–714.1)
Clozapine 14 (3.3) 162.85 (97.54–228.17) 25–400 244.28 (146.31–342.25)
Haloperidol 9 (2.1) 6.54 (2.89–10.19) 2.5–15 392.66 (173.91–611.41)
Ziprasidone 3 (0.7) 62.44 (-61.0433–185.93) 60–160 234.16 (-228.91–697.23)
Perfenazine 3 (0.7) 8 8 160
Clotiapine 2 (0.5) 20 20 120
Zuclopenthixol 1 (0.2) 100 100 1200
Pimozide 1 (0.2) 1.5 1.5 112.5
PPD is shown in milligrams; the 95% confidence intervals of the mean are given in brackets.
Table 3. Cumulative Daily Dose of Antipsychotics, Separated by Gender, Diagnosis, and Concomitant Treatment with Anticholinergic Drugs, 
Antidepressants, Mood Stabilizers, and Benzodiazepines
Statistic P-Value
Gender Males
(n = 203)
Females
(n = 99)
529.99 ± 26.93 414.9 ± 23.78 U = 11487.5 .043
Diagnosis Nonaffective psychosis
(n = 253)
Affective psychosis
(n = 49)
494.12 ± 20.91 482.67 ± 59.14 t = 0.21 .83
Use of anticholinergic drugs Yes
(n = 39)
No
(n = 263)
705.34 ± 63.25 460 ± 20.21 t = 4.23 <.001
Use of antidepressants Yes
(n = 39)
No
(n = 263)
476.08 ± 63.91 494 ± 20.88 t = -0.31 .75
Use of mood stabilizers Yes
(n = 40)
No
(n = 262)
528.94 ± 69.77 486.66 ± 20.4 t = 0.71 .473
Use of benzodiazepines Yes
(n = 118)
No
(n = 184)
524.98 ± 32.58 471.28 ± 25.12 t = 1.31 .18
The mean dose is expressed as chlorpromazine equivalents (mg/d).
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treated with monotherapy (85.2% vs 45.5%), showing statistical 
significant differences (χ2 = 15.1; P < .001).
Direct logistic regression was performed to assess the impact 
of these 2 factors (antipsychotic doses and antipsychotic poly-
therapy) on the likelihood that any ADRs would be reported. 
The full model containing all predictors was statistically sig-
nificant (χ2 [2, n = 237] = 18.76, P < .001), indicating that the model 
was able to distinguish between patients who did and did not 
report ADRs. The model as a whole explained between 7.6% 
(Cox and Snell R square) and 10.1% (Nagelkerke R squared) of 
the variance in ADR presence and correctly classified 61.6% of 
cases. Only antipsychotic polytherapy made a unique statisti-
cally significant contribution to the model with an odds ratio 
of .206 (P = .008), indicating that using a polytherapy treatment 
increased 4.85 (1/0.206) times the likelihood of reporting having 
any ADRs, controlling for other factors in the model.
On the other hand, other approaches to find variables asso-
ciated with reports of ADRs, related to the possible interaction 
between age, gender, and nonaffective/affective diagnosis, the 
time of evolution of the disease, or the use of other psychotropic 
drugs, did not reach a statistically significant relationship.
In those patients treated with monotherapy, the appear-
ance of ADRs was related more to the prescription of quetiapine 
(62.2% reported at least one ADR) and risperidone (50%), while 
the least were clozapine (25%) and amisulpride (33%).
Sixty-eight (22.5%) of the 302 cases that completed the phar-
macovigilance period reported a specific treatment for their 
adverse events, including antipsychotic stop, dose reduction, or 
initiation of an anticholinergic drug (see Table 4 for details).
Table  4 also shows strategies reported by the investigators 
to alleviate ADRs. An antipsychotic dose reduction was recom-
mended in 13 patients, with a mean dose reduction of 21.1% 
in CPZ equivalents. In 15 patients, an antipsychotic change was 
introduced; the change to aripiprazole in monotherapy was the 
most frequent (n = 7).
Discussion
This article describes the baseline treatment characteristics and 
a 2-month pharmacovigilance period of the 335 patients with a 
FEP included in the PEPs project, a multicenter, prospective, lon-
gitudinal, naturalistic, follow-up study conducted at 16 research 
sites in Spain. According to these data, after suffering a FEP, the 
majority of patients receive a SGA (96.3%), via oral administra-
tion (95%), in adjusted dosage according to the product specifica-
tion in our country (87.2%), and more frequently in monotherapy 
(68.7%). Together, these data offer an overall picture of the phar-
macologic prescription for treating this population in Spain.
One of the main objectives of the present article was ascer-
tain to what extent drug prescriptions followed the recommen-
dations of the principal clinical practice guidelines. At present, 
there is a clinical practice guideline for schizophrenia and incip-
ient psychotic disorder driven by the Spanish Ministry of Health 
in which evidence-based recommendations are collected (Grupo 
de trabajo de la Guía de Práctica Clínica sobre la Esquizofrenia y 
el Trastorno Psicótico Incipiente. Fòrum de Salut Mental, 2009). 
Several international guidelines, such as those of the German 
Society of Psychiatry, Psychotherapy and Nervous Disease 
(Deutsche Gesellschaft für Psychiatrie Psychotherapie und 
Nervenheilkunde, 2006), the American Psychiatric Association 
(American Psychiatric Association, 2004), and the National 
Institute of Clinical Excellence (National Institute of Clinical 
Excellence, 2009), publish similar recommendations. Regarding 
specific pharmacological interventions in FEP, the follow-
ing core principles are outlined in these guidelines (American 
Psychiatric Association, 2004; Deutsche Gesellschaft für 
Psychiatrie Psychotherapie und Nervenheilkunde, 2006; Grupo 
de trabajo de la Guía de Práctica Clínica sobre la Esquizofrenia 
y el Trastorno Psicótico Incipiente. Fòrum de Salut Mental, 2009; 
National Institute of Clinical Excellence, 2009). According to the 
current state of research on pharmacological intervention in 
FEP, there is not enough scientific evidence to indicate a FGA vs a 
SGA. However, some studies indicate that there could be greater 
adherence with SGAs, supporting their use as a first election 
(Zhang et  al., 2013). The onset of the administration of SGA 
antipsychotics should be at low doses. If there is no response to 
treatment, switch to another SGA and evaluate the result for 6 
to 8 weeks. If while using an SGA an adverse effect occurs, one 
might consider switching to a FGA. It is recommended to use 
clozapine in cases where there is no response to treatment, low 
adherence, or persistent risk of suicide.
In 2009 the PORT guidelines pointed out that “antipsychotic 
medications, other than clozapine and olanzapine, are recom-
mended as first-line treatment for persons with schizophre-
nia experiencing their first acute positive symptom episode” 
(Buchanan et al., 2010), arguing that both drugs can cause seri-
ous metabolic side effects. This recommendation was poorly 
followed in our study, particularly in the case of olanzapine;: 
it was included in the 27.1% of the prescriptions and was the 
most used antipsychotic in monotherapy (n = 76). As the PORT 
guidelines were published in the middle of the inclusion period 
(January, 2010)  and, to our knowledge, this recommendation 
has not been included in other treatment guidelines to date, 
this question deserves a special attention in the future studies 
with FEP.
Regarding the choice of an FGA vs SGA, a recent meta-anal-
ysis indicated that, in first episodes of schizophrenia, determi-
nate SGA show superior efficacy, greater treatment persistence 
and less EPS than FGA, but also a major weight increase and 
metabolic changes, specially in the case of olanzapine (Zhang 
Table 4. Adverse Drug Reactions (ADRs) Reported during the Phar-
macovigilance Period
Number of Patients
(% Total Patients; n = 335)
Number of ADRs reported
None 216 (64.48)
1 74 (22.08)
2 30 (8.95)
3 13 (3.88)
4 2 (0.6)
Types of ADRs
Extrapyramidal symptoms 58 (9.9)
Sedation 44 (7.5)
Headache 4 (0.7)
Weight gain 19 (3.2)
Sexual side effects 11 (1.9)
Cognitive/negative 9 (1.5)
Sialorrea 3 (0.5)
Hormonal 12 (2)
Others 21 (3.6)
Treatment for ADRs
Antipsychotic dose reduction 13 (3.8)
Antipsychotic change 15 (4.5)
Anticholinergic 29 (8.6)
Others 9 (2.6)
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et  al., 2013). In a multiple-treatments meta-analysis including 
15 antipsychotic drugs in schizophrenia, Leucht et  al. (2013) 
also remarked that antipsychotics differed substantially in 
side effects and that small but robust differences were seen in 
efficacy, pointing out that classification of antipsychotics into 
first-generation and second-generation groupings is too simple 
and uninformative and that the SGA group is too heterogene-
ous. In any case, from our naturalistic study, it becomes clear 
that Spanish psychiatrists clearly prefer starting treatment with 
a SGA, generally in low to medium doses, and that in case of a 
bad response or side effects, the second option to switch uses 
to be a SGA too.
Another point of focus in our study is the use of antipsy-
chotic polytherapy. This is a common practice in everyday clini-
cal practice, although there is little scientific evidence to support 
its use over other strategies (Bernardo et  al., 2012; Tani et  al., 
2013). In our study, this practice was related more to inadequate 
dosage. Antipsychotic polytherapy was also related to the pres-
ence of ADRs, being a more relevant factor than antipsychotic 
dosage in CPZ equivalents. This result points to the fact that 
antipsychotic polytherapy is unsafe not only because the result 
dosage is higher, but for other factors intrinsic to this practice 
related to phenomena such as drug interactions or mechanism 
of actions.
Only 8 patients were receiving clozapine. It was used in mon-
otherapy in all cases in low doses compared with other strate-
gies and generally well-tolerated. To our knowledge, there are 
only 2 clinical trials that have compared the use of clozapine in 
FEPs; one vs CPZ and the other vs risperidone (Girgis et al., 2011; 
Sanz-Fuentenebro et al., 2013), pointing to a slightly greater tol-
erability and greater time in remission efficacy, specifically in 
relation to treatment adherence. According to these data, low/
medium doses of clozapine in monotherapy might be better tol-
erated than an antipsychotic polytherapy prescription, although 
the clozapine group is too small to make adequate statistical 
comparisons.
Another point of interest was to characterize the use of 
LAIAs formulations in this broad sample of FEPs. These for-
mulations have traditionally been used at latter stages for 
those patients with schizophrenia with the most severe symp-
toms, poorest adherence, most relapses, and generally poor-
est outcomes (Tiihonen et al., 2011; Stahl, 2014). Some clinical 
guidelines, including the Spanish one, maintain these recom-
mendations (Grupo de trabajo de la Guía de Práctica Clínica 
sobre la Esquizofrenia y el Trastorno Psicótico Incipiente. Fòrum 
de Salut Mental, 2009). However, some authors defend that 
early-phase patients may have the most to gain from LAIAs at 
a time when their disorder is most treatable and when avoid-
ance of recurrences and rehospitalizations may lead to the big-
gest gains in outcome (Tiihonen et  al., 2011; Stahl, 2014) and 
decreasing complications associated with noncompliance, such 
as substance abuse, violence, legal conflicts, and treatment 
resistance (Zhornitsky and Stip, 2012; Stahl, 2014). Some clini-
cal guidelines, like the Canadian one, are beginning to include 
the recommendation to use LAIAs in patients in early stages of 
the disorder (Malla et al., 2013; Manchanda et al., 2013). Despite 
these reported advantages, only a small proportion (5.2%) of the 
patients at baseline of the PEPs project were receiving LAIAs, all 
with risperidone LAI and only one without oral supplementa-
tion. Being a 2-year follow-up study, it is possible that this per-
centage of use of LAIAs will increase in successive controls. This 
proportion could also be increased with the recent appearance 
of new second-generation LAIAs, such as olanzapine, paliperi-
done, and aripiprazole (Patel et al., 2010).
Looking at the use of other psychotropic drugs, a consid-
erable percentage of patients received anticholinergic drugs 
(12.2%), a percentage that is consistent with the literature about 
their use in FEPs (Rybakowski et al., 2014). Males received sig-
nificantly higher doses of antipsychotics and were prescribed 
anticholinergic drugs more frequently. The presence of 16.4% of 
affective psychoses in the sample explains, at least in part, the 
percentages of antidepressant (12.2%) or mood stabilizer (13.7%) 
prescription, which were clearly associated with this subgroup 
of patients. Almost 40% of the patients received benzodiaz-
epines. A  relatively recent Cochrane’s review about the use of 
benzodiazepines in schizophrenia and related disorders showed 
that there is no convincing evidence to confirm or refute its use 
(Dold et al., 2012). Evidence suggests that benzodiazepines are 
effective for very short-term sedation and could be considered 
for calming acutely agitated patients, generally with adequate 
acceptability (Dold et al., 2012). It should be noted that, in our 
sample, the use of other psychotropic drugs was not associated 
to a major risk of presenting ADRs.
Around 35% of the patients reported ADRs; extra-pyramidal 
symptoms, sedation, and weight gain were the most common. 
Diverse changes in antipsychotic dosage and new treatments 
were introduced because of these adverse events. A  detailed 
description of these ADRs and their association with pharmaco-
genetic characteristics of the subjects will be published in future 
reports.
A benefit of our study is that it allows a comparison of 
these prescribing practices in Spain with other similar samples 
elsewhere in the world. In this vein, the RAISE study recently 
described these practices in a comparable sample of 404 first 
episodes of schizophrenia in 21 states in the USA from July 2010 
to July 2012 (Robinson et al., 2015). At first glance, there are simi-
lar findings between the RAISE and PEPs studies: (1) the propor-
tion of patients treated with antipsychotics was high (83.4% vs 
91%), generally in monotherapy (89% vs 81.1%); (2) the 2 more 
prescribed antipsychotics were olanzapine and risperidone 
(representing together 53–56% of the prescriptions), but with dif-
ferent proportions in monotherapy (more frequent with risperi-
done in the RAISE study); (3) women received significantly lower 
mean doses of antipsychotics; and (4) the prescription of mood 
stabilizers was approximately 10%. Given that clinical settings in 
the US and Europe are different, there are significant differences 
between both studies in some aspects, such as ethnic diversity 
(much higher in the RAISE study) or patients’ health coverage 
(which may explain the lower prescription of FGA in Spain 3.7% 
vs 11.9%, more associated with patients without medical cov-
erage in the RAISE study). A major proportion of FGA prescrip-
tions could also explain that the proportion of patients receiving 
anticholinergic drugs was higher in the US than in Spain (21.1% 
vs 12.2%). The use of LAIAS frequencies (9.5% vs 5.2%) could also 
be different, because paliperidone palmitate was not yet avail-
able in Spain during the study period. Other relevant differences 
may be related to the study design. The presence of an affective 
disorder (bipolar or unipolar) was an exclusion criterion in the 
RAISE study, while it represented 16.4% of the PEPs sample. This 
could explain why there is a greater percentage of olanzapine 
treatment. Besides different prescription habits between psy-
chiatrists, all patients in the RAISE study were recruited in com-
munity settings, which could explain, at least in part, a much 
higher use of antidepressants (31.9% vs 12.2%) and much lower 
use of anxiolytic/sedative agents (15.4% vs 38.8%).
There are some limitations in this study that should be 
taken into consideration. Due to its naturalistic design and by 
the very nature of the sample included, some recommendations 
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included in clinical practice guideline (such as the conveni-
ence of a period of 24–48 hours of observation before starting 
the antipsychotics, the 12-month minimum duration of an 
effective treatment, or interventions for detecting and treating 
low adherence) could not be evaluated in this study (American 
Psychiatric Association, 2004; Deutsche Gesellschaft für 
Psychiatrie Psychotherapie und Nervenheilkunde, 2006; Grupo 
de trabajo de la Guía de Práctica Clínica sobre la Esquizofrenia 
y el Trastorno Psicótico Incipiente. Fòrum de Salut Mental, 2009; 
National Institute of Clinical Excellence, 2009). It should also be 
taken into consideration when extrapolating results that the 
major part of the participants are tertiary care centers linked to 
universities and to CIBERSAM, so both the patient sample and 
therapeutic strategies may differ from those used in other areas.
A strength of our study is that that the diagnostic evaluation 
was performed with a very comprehensive protocol with strict 
inclusion-exclusion criteria (Bernardo et al., 2013; Bioque et al., 
2013), making this sample much closer to the “real life” FEP pop-
ulation. Because of the heterogeneity of schizophrenia as a clini-
cal entity, the FEP subgroup is of great interest, because it avoids 
the effect of confounding variables, such as prolonged antipsy-
chotic treatment or chronicity (Bertani et al., 2011; Kapur et al., 
2012; Bernardo et al., 2013; Bernardo and Bioque, 2014). Another 
key feature of this study is that the age of inclusion is wider than 
in other previous works, including adolescents. To our knowl-
edge, there are no previous, similar studies in Spain. While we 
cannot claim the sample is representative, all/most participat-
ing hospitals cover a health area in the National Health System, 
and therefore the study may give a good perspective of what is 
presently the clinical practice in this country.
In conclusion, these results indicate that overall pharmaco-
logic prescription for treating a FEP in Spain follows the recom-
mendations of major medical guidelines for clinical practice. 
There is a considerable use of anticholinergic and antidepressant 
drugs, while the prescription of benzodiazepines remarkably 
high. While almost one-quarter of the patients were treated with 
antipsychotic polytherapy, only a small proportion of patients 
was treated with clozapine or LAIAs. More than one-third of the 
FEP report at least one ADR, being more related to antipsychotic 
polytherapy patterns than to high antipsychotic dosage.
Together with previous findings, this study supports the 
future research of determinate pharmacological strategies for 
the treatment of patients in early phases of psychotic disorders, 
such as the role of clozapine, LAIAs, and antipsychotic combina-
tion, together with security issues.
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